Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H2 2016
Summary
Publisher's, 'Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H2 2016', provides in depth analysis on Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted pipeline therapeutics.
The report provides comprehensive information on the Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development and features dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.
Scope
- The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
- The report reviews Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables 5
List of Figures 5
Introduction 6
Publisher Report Coverage 6
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Overview 7
Therapeutics Development 8
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Products under Development by Stage of Development 8
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Products under Development by Therapy Area 9
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Products under Development by Indication 10
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Products under Development by Companies 14
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Products under Development by Universities/Institutes 16
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Companies Involved in Therapeutics Development 24
Biomics Biotechnologies Co., Ltd. 24
Bioneer Corporation 25
Boehringer Ingelheim GmbH 26
MimiVax, LLC 27
Optimum Therapeutics, LLC 28
Polyplus-Transfection SA 29
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Drug Profiles 30
Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Antisense RNAi Oligonucleotide to Inhibit Survivin for Solid Tumors - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
BI-1361849 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
BKM-1644 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
BKM-1740 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
C-10M - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
FL-118 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
MX-106 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
UC-112 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Vaccine for Lymphoma and Colon Carcinoma - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Vaccine for Oncology - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Vaccine to Target Survivin for Glioblastoma Multiforme and Multiple Myeloma - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Dormant Projects 50
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Discontinued Products 53
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Featured News & Press Releases 54
May 31, 2016: Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer 54
Sep 09, 2015: Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study 55
Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies 55
Apr 21, 2015: SurVaxM Phase I Completed 56
Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer 57
Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent 58
Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent 59
Nov 04, 2013: CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer 60
Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent 61
Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64
List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016 24
Pipeline by Bioneer Corporation, H2 2016 25
Pipeline by Boehringer Ingelheim GmbH, H2 2016 26
Pipeline by MimiVax, LLC, H2 2016 27
Pipeline by Optimum Therapeutics, LLC, H2 2016 28
Pipeline by Polyplus-Transfection SA, H2 2016 29
Dormant Projects, H2 2016 50
Dormant Projects (Contd..1), H2 2016 51
Dormant Projects (Contd..2), H2 2016 52
Discontinued Products, H2 2016 53
List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Routes of Administration, H2 2016 20
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 22
Biomics Biotechnologies Co., Ltd.
Bioneer Corporation
Boehringer Ingelheim GmbH
MimiVax, LLC
Optimum Therapeutics, LLC
Polyplus-Transfection SA
Global Joint Replacement Market 2019 by ..
Replacement arthroplasty, or joint replacement surgery, is a..
+1-646-491-9876US (Toll Free)